Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PVLA vs RAPP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PVLA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–2 Matrix Metrics)

PVLA Overall Winner 6-Pillar Tally: PVLA 2 – 2 RAPP (2 Tie) Matrix Metrics: PVLA 4 – 2 RAPP

As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Rapport Therapeutics, Inc. (RAPP) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas RAPP carries 51.5/100 (HOLD) at $25.29 (N/M Forward P/E, -838.1% operating margin).

  • Composite vs. Pillar Nuance: While RAPP currently prints a higher short-term Unified Composite Score (51.5/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -838.1% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile RAPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PVLA vs RAPP
PVLA NASDAQ Head-to-Head Winner
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42
RAPP NASDAQ
Rapport Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$25.29
-3.29% 1D
Market Cap $1.5B
TTM Revenue $20M
Forward P/E N/M
Beta / 30D Vol 1.34β · 109% Vol
Unified Composite Score
51.5 / 100 HOLD
Tech 64.0 Fund 60.0 Flow 68.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.6%), weak momentum, RSI 42
RSI-14: 41.6 · SMA20: $25.61 · SMA50: $31.51

6-Pillar Scorecard Institutional Category Breakdown (PVLA 2 – 2 RAPP)

Columns: Metric · PVLA · RAPP
1. Valuation Multiples RAPP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 73.4x
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $20M
Market Cap $2.2B $1.5B
3. Profitability & Quality PVLA
Gross Margin N/A N/A
Operating Margin 0.0% -838.1%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -63.4% -33.3%
4. Balance Sheet & Cash Flow PVLA
Cash Generation (TTM) -$43M -$121M
Cash Flow Margin N/A N/A
Net Cash / Leverage $193M Net Cash $65M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RAPP
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 47.9% (2nd %ile) 93.8% (6th %ile)
Put/Call OI Skew 3.82x (Put-Skewed) 0.91x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PVLA (4) vs RAPP (2)
Institutional Metric PVLA RAPP Criterion Row Edge
Market Capitalization
Scale
$2.2B $1.5B Larger Scale PVLA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% -838.1% Higher Margin PVLA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-63.4% -33.3% Higher ROE RAPP
52-Week Range Position
Momentum
68% ($72–$180) 10% ($22–$53) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.66β · 75% Vol 1.34β · 109% Vol Lower Realized Risk PVLA
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 51.5 / 100 (HOLD) Higher Composite RAPP
Trailing 12M Revenue (USD)
Operating Scale
N/A $20M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 73.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$43M ($193M Net Cash) -$121M ($65M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +28.83 pp
PVLA: +20.56% · RAPP: -8.27%
3M Horizon PVLA +44.82 pp
PVLA: -3.58% · RAPP: -48.4%
6M Horizon PVLA +66.17 pp
PVLA: +38.06% · RAPP: -28.11%
1Y Horizon PVLA +77.65 pp
PVLA: +80.16% · RAPP: +2.51%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PVLA vs RAPP. Trailing 12-month operating profitability (PVLA 0.0% vs RAPP -838.1%) and valuation multiples (PVLA N/M vs RAPP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PVLA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-63.4% · N/M
RAPP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross MarginN/A
Op. Margin-838.1%
ROE / Fwd P/E-33.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RAPP BREAKDOWN
133d in phase · OBV NEUTRAL
Current IV 93.8%
IV Percentile 6th %ile
Put/Call OI Skew 0.91x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RAPP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RAPP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -838.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PVLA vs RAPP Key Questions & Quantitative Answers

As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Rapport Therapeutics, Inc. (RAPP) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas RAPP carries 51.5/100 (HOLD) at $25.29 (N/M Forward P/E, -838.1% operating margin). Composite vs. Pillar Nuance: While RAPP currently prints a higher short-term Unified Composite Score (51.5/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -838.1% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile RAPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PVLA and RAPP split Growth & Scale metrics: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with RAPP at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (N/A gross margin, -838.1% operating margin). On trailing 12-month operating scale, PVLA generates N/A in USD-normalized revenue versus $20M for RAPP. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPP.

RAPP screens cheaper on headline valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RAPP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 73.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus RAPP (-33.3% ROE) capital efficiency.

In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, RAPP carries 93.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.91x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.34β · 109% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.